Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 16 July 2021 | By Jeff Craven 

COVID-19 therapeutics tracker

More than a year into the pandemic, only a handful of repurposed therapeutics have been approved to treat COVID-19: dexamethasone in the UK and Japan; Avigan (favilavir) in China, Italy and Russia; and Veklury (remdesivir) in the US, UK and Japan.
 
Regulators around the world have allowed a handful of treatments to be used on an emergency-use basis including Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology's sotrovimab; Roche's Actemra; Celltrion's Regkirona; and convalescent plasma. 
 
Several large international trials are underway. The largest, SOLIDARITY, is led by the World Health Organization (WHO). More than 100 countries have joined SOLIDARITY to evaluate high-profile treatment candidates for COVID-19.

This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at news@raps.org.
 
Updated 16 July to include new information on Actemra, AT-527, bamlanivimab/etesevimab, casirivimab/imdevimab, dexamethasone, heparin, ivermectin, Kevzara, molnupiravir, Pyramax, Regkirona, sotrovimab and Veklury.

 

 

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe